Publications 2016

Cain LE, Caniglia EC, Phillips A, Olson A, Muga R, Pérez-Hoyos S, et al. Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-positive individuals. Medicine (Baltimore). oct 2016;95(41):e5133. Disponible sur:

Cain LE, Saag MS, Petersen M, May MT, Ingle SM, Logan R, et al. Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. Int J Epidemiol. 1 déc 2016;45(6):2038‑49. Disponible sur:

Caniglia EC, Sabin C, Robins JM, Logan R, Cain LE, Abgrall S, et al. When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries: A Prospective Observational Study. J Acquir Immune Defic Syndr. 1 juin 2016;72(2):214‑21. Disponible sur:

Cancer Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCoord. Changing Incidence and Risk Factors for Kaposi Sarcoma by Time Since Starting Antiretroviral Therapy: Collaborative Analysis of 21 European Cohort Studies. Clin Infect Dis. 15 nov 2016;63(10):1373‑9. Disponible sur:

May MT, Vehreschild J-J, Trickey A, Obel N, Reiss P, Bonnet F, et al. Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study. Clin Infect Dis. 15 juin 2016;62(12):1571‑7. Disponible sur:

de Monteynard L-A, Matheron S, Gilquin J, Pavie J, de Truchis P, Grabar S, et al. Influence of geographic origin, sex, and HIV transmission group on the outcome of first-line combined antiretroviral therapy in France. AIDS. 2016;30(14):2235‑46. Disponible sur:

Olson AD, Walker AS, Suthar AB, Sabin C, Bucher HC, Jarrin I, et al. Limiting Cumulative HIV Viremia Copy-Years by Early Treatment Reduces Risk of AIDS and Death. J Acquir Immune Defic Syndr. 1 sept 2016;73(1):100‑8. Disponible sur:

Pantazis N, Touloumi G, Meyer L, Olson A, Costagliola D, Kelleher AD, et al. The impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunologic response in later treatment. AIDS. 27 mars 2016;30(6):879‑88. Disponible sur:

Pediatric AIDS-Defining Cancer Project Working Group for IeDEA Southern Africa, TApHOD and C in E, Rohner E, Schmidlin K, Zwahlen M, Chakraborty R, Clifford G, et al. Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. Clin Infect Dis. 1 nov 2016;63(9):1245‑53. Disponible sur:

Potard V, Simon A, Lacombe J-M, Parienti J-J, Costagliola D, French Hospital Database on HIV (FHDH-ANRS CO4). Switching to Raltegravir From a Virologically Effective Boosted Protease Inhibitor Regimen: A Comparative Effectiveness Analysis From the French Hospital Database on HIV (FHDH-ANRS CO4). Clin Infect Dis. 1 nov 2016;63(9):1254‑61. Disponible sur:

Supervie V, Marty L, Lacombe J-M, Dray-Spira R, Costagliola D, FHDH-ANRS CO4 study group. Looking Beyond the Cascade of HIV Care to End the AIDS Epidemic: Estimation of the Time Interval From HIV Infection to Viral Suppression. J Acquir Immune Defic Syndr. 1 nov 2016;73(3):348‑55. Disponible sur:

Trickey A, May MT, Vehreschild J, Obel N, Gill MJ, Crane H, et al. Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy. PLoS One. 1 août 2016;11(8):e0160460. Disponible sur: